ATE184883T1 - Muramylverbindungen zur behandlung von septischem schock - Google Patents

Muramylverbindungen zur behandlung von septischem schock

Info

Publication number
ATE184883T1
ATE184883T1 AT92923873T AT92923873T ATE184883T1 AT E184883 T1 ATE184883 T1 AT E184883T1 AT 92923873 T AT92923873 T AT 92923873T AT 92923873 T AT92923873 T AT 92923873T AT E184883 T1 ATE184883 T1 AT E184883T1
Authority
AT
Austria
Prior art keywords
muramyl
pct
acetyl
date
septic shock
Prior art date
Application number
AT92923873T
Other languages
English (en)
Inventor
Roger Aston
Original Assignee
Peptech Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919124500A external-priority patent/GB9124500D0/en
Priority claimed from GB929210013A external-priority patent/GB9210013D0/en
Application filed by Peptech Uk Ltd filed Critical Peptech Uk Ltd
Application granted granted Critical
Publication of ATE184883T1 publication Critical patent/ATE184883T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT92923873T 1991-11-19 1992-11-19 Muramylverbindungen zur behandlung von septischem schock ATE184883T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919124500A GB9124500D0 (en) 1991-11-19 1991-11-19 Compounds for medicinal use
GB929210013A GB9210013D0 (en) 1992-05-08 1992-05-08 Compounds for medicinal use

Publications (1)

Publication Number Publication Date
ATE184883T1 true ATE184883T1 (de) 1999-10-15

Family

ID=26299886

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92923873T ATE184883T1 (de) 1991-11-19 1992-11-19 Muramylverbindungen zur behandlung von septischem schock

Country Status (9)

Country Link
US (1) US5506204A (de)
EP (1) EP0615522B1 (de)
JP (1) JP3628689B2 (de)
AT (1) ATE184883T1 (de)
AU (1) AU666890B2 (de)
CA (1) CA2123912C (de)
DE (1) DE69230041T2 (de)
RU (1) RU2139086C1 (de)
WO (1) WO1993010148A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
GB9413935D0 (en) * 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
GB9419011D0 (en) * 1994-09-21 1994-11-09 Peptech Uk Ltd Use of muramyl peptide compounds
WO1997005889A1 (en) * 1995-08-03 1997-02-20 Slesarev Vladimir I Non-specific vaccination by d-amino-acid containing compounds
US6200955B1 (en) * 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US5834435A (en) * 1996-11-27 1998-11-10 Slesarev; Vladimir I. Inhibition of TNF-α pleiotropic and cytotoxic effects
CA2320962C (en) 1998-02-13 2011-04-19 Amylin Pharmaceuticals, Inc. Novel mixed amylin activity compounds
HUP0303579A3 (en) 2000-04-18 2004-03-29 Lilly Co Eli Process for preparing lipid ii and derivatives thereof
WO2001079268A2 (en) * 2000-04-18 2001-10-25 Eli Lilly And Company A glycopeptide and preparation thereof
US7112564B2 (en) * 2003-04-09 2006-09-26 Zylacta Corporation Biodegradable glucosaminemuramyl peptides for apoptosis modulation
WO2005007676A2 (en) * 2003-07-10 2005-01-27 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
RU2412197C2 (ru) * 2006-07-06 2011-02-20 Попилюк Сергей Федорович Полимерный фрагмент пептидогликана клеточной стенки грамотрицательных бактерий, способ его получения и его применение в качестве иммуностимулятора
ES2856081T3 (es) 2007-04-16 2021-09-27 Occlutech Holding Ag Oclusor para la oclusión de una orejuela auricular y procedimiento de producción del mismo
EP2209476A4 (de) 2007-04-19 2011-01-19 Univ Pittsburgh Verwendung von toll-like rezeptor-9-agonisten; toll-like rezeptor-4-antagonisten und/oder nuklearen oligomerisierungs-domäne-2-agonsiten zur behandlung oder prävention von erkrankungen im zusammenhang mit toll-like rezeptor-4
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
RU2336897C1 (ru) * 2007-04-28 2008-10-27 Федеральное государственное учреждение здравоохранения "Ростовский-на-Дону научно-исследовательский противочумный институт" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ терапии токсического шока у лабораторных животных при экспериментальной чуме
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
WO2014052453A1 (en) 2012-09-25 2014-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
EA025690B1 (ru) * 2014-07-15 2017-01-30 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Ранозаживляющее средство, обладающее иммуностимулирующим и антиоксидантным эффектами
RU2584089C1 (ru) * 2015-06-15 2016-05-20 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Саратовский Государственный Медицинский Университет Имени В.И. Разумовского" Министерства Здравоохранения Российской Федерации Способ снижения летального эффекта бактериального липополисахарида in vitro
EP4014967A1 (de) 2016-04-29 2022-06-22 Icahn School of Medicine at Mount Sinai Abzielung auf das angeborene immunsystem zur induzierung von langfristiger toleranz und auflösung von makrophagenakkumulation bei atherosklerose
CN118459539B (zh) 2021-03-19 2026-01-06 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU727647A1 (ru) * 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Гликопептиды,обладающие противоопухолевой активностью и способ их получени
JPS5543030A (en) * 1978-09-21 1980-03-26 Dai Ichi Seiyaku Co Ltd Prophylactic and remedy for microbial infection disease
FR2449697A1 (fr) * 1979-02-20 1980-09-19 Anvar Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant
AU609524B2 (en) * 1987-09-02 1991-05-02 Daiichi Pharmaceutical Co., Ltd. Method for preventing or treating thrombocytopenia
SU1671310A1 (ru) * 1989-01-30 1991-08-23 Всесоюзный Научно-Исследовательский Институт Экспериментальной Ветеринарии Им.Я.Р.Коваленко Способ профилактики вирусных заболеваний птиц

Also Published As

Publication number Publication date
EP0615522B1 (de) 1999-09-22
DE69230041T2 (de) 2000-01-05
US5506204A (en) 1996-04-09
JP3628689B2 (ja) 2005-03-16
RU94027574A (ru) 1996-07-20
JPH07508497A (ja) 1995-09-21
EP0615522A1 (de) 1994-09-21
RU2139086C1 (ru) 1999-10-10
DE69230041D1 (de) 1999-10-28
CA2123912C (en) 2007-04-17
AU2949292A (en) 1993-06-15
CA2123912A1 (en) 1993-05-27
WO1993010148A1 (en) 1993-05-27
AU666890B2 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
DE69230041D1 (de) Muramylverbindungen zur behandlung von septischem schock
DE69421912D1 (de) Methode zur behandlung von wasser
ZA963593B (en) IL-6 activity inhibitor
GB9323165D0 (en) Compounds
PT988301E (pt) Acetais ciclicos de imidazolilo
DE69331665D1 (de) Methode zur behandlung von nukleinsäureproben
DE69527765D1 (de) Verwendung von Hyaluronsäure oder sein Salz zur Behandlung von Hauterkrankungen
ATE192045T1 (de) Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose
DE69203828D1 (de) Verfahren zur behandlung von produkten roter blutkörperchen zur langzeitlagerung frei von mikroorganismen.
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE59201870D1 (de) Verfahren zur Herstellung von substituierten Malonesteraniliden und Malonsäure-monoaniliden.
DE69504180D1 (de) Bestimmung des genesungszustandes von knochen nach fraktur
GB9506684D0 (en) Control of pod dehiscence
DE69129953D1 (de) Verwendung von Bisphosphonsäure zur Behandlung von Störungen des Kalziummetabolismus
DE59202663D1 (de) Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
ATE198751T1 (de) Azoderivate von 5-aminosalicylsäure zur behandlung von enzündlichen darmerkrankungen
DE69328615D1 (de) Verfahren zur behandlung von viehhaltungsgülle
DE69300667D1 (de) Verfahren zur thermischen Behandlung von verbrauchten Auskleidungen aus elektrolytischen Hall-Heroult Zellen.
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
FR2672895B1 (fr) Procede de purification d'une proteine fortement glycosylee.
ATE209891T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE68907386D1 (de) Verwendung von phytinsaeure oder deren salzen zur verhinderung oder behandlung von lebererkrankungen.
DE69634411D1 (de) Methode zur kontrolle der züchtung von milchsäurebakterien
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
DE69404725D1 (de) Verfahren zur elektrolytischen Behandlung von Altbatterien